• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

Govtempdiary

  • Home
  • 7th CPC Calculator
  • Pay Matrix
  • AICPIN

8th Pay CommissionPay Matrix
AICPINDA Calculator 2025

CGHS Implements CDSCO Guidelines for Procurement & Issue of Bio-similar Medicines

March 3, 2023 by Eliza Leave a Comment

The Indian Ministry of Health and Family Welfare’s Central Government Health Scheme (CGHS) has issued a policy on bio-similar medicines for procurement and issuance to CGHS beneficiaries. The regulatory authority for drug approval in India, the Central Drug Standard Control Organization’s Biological Division, defines bio-similar medicines as similar in terms of quality, safety, and efficacy to an approved reference biological product based on comparability. The policy states that bio-similar medicines procured and issued to CGHS beneficiaries should be on par with the reference authorized biologic/original biologic molecule/formulation of biologic medicine in accordance with the CDSCO’s guidelines. The memorandum was approved by Dr. Anjana Rajkumar, the Director of CGHS, on 8th February 2023.

Policy on Bio-similar medicines in CGHS for purpose of procurement and issue to CGHS Beneficiaries

File No. 1-1/22-23/CGHS/MSDI/3570884/2023
भारत सरकार
स्‍वास्‍थ्‍य और परिवार कल्‍याण मंत्रालय
महानिदेशालय, के.स.स्‍वा.यो.
निर्माण भवन, मौलाना आजाद रोड, नई दिल्‍ली

545-ए निर्माण भवन, नई दिल्‍ली
Dated:08-02-2023

कार्यालय ज्ञापन/ OFFICE MEMORANDUM

Subject: Policy on Bio-similar medicines in CGHS for purpose of procurement and issue to CGHS Beneficiaries

The Central Drug Standard Control Organization’s (CDSCO) Biological Division is the regulatory authority for approval of drugs in India, and issues guidelines of bio-similar medicine/drugs. The guidelines define biosimilar as “a similar biologic product which is similar in terms of quality, safety and efficacy to an approved Reference’ Biological product based on comparability”.

Therefore, it has been decided that, for the purpose of procurement & issue to CGHS beneficiaries, the bio-similar medicine shall be at par with the reference authorized biologic/original biologic molecule/formulation of biologic medicine on the lines of guideline issued by CDSCO in this regard.

Signed by Anjana Rajkumar
Date: 08-02-2023 14:40:01
Reason: Approved
(डा. अंंजना राजकुमार)
Director CGHS
Tel No. 011-23062800

Filed Under: CGE Latest News, CGHS, Recent govt orders

Recent Posts

  • 8th Pay Commission: Major Salary Hike Expected for Government Employees January 16, 2025
  • CPI-IW November 2024 Update – All-India Consumer Price Index January 6, 2025
  • EPFO UAN Activation 2024: AADHAAR Seeding Guidelines for ELI Scheme December 16, 2024
  • EPS Pension Increase: Updates on Minimum Pension Hike for 2024 December 13, 2024
  • Good News for Ex-Servicemen: ECHS Gets a Major Boost December 12, 2024

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Primary Sidebar

  • Home
  • 8th Pay Commission
  • 7th CPC Calculator [updated]
  • Pay Matrix
  • Dopt orders
  • DA News
  • AICPIN
  • DA 2024
  • DA Calculator 2025
  • Superannuation Date Calculator

GET FREE EMAIL UPDATE

Secondary Sidebar

Categories

Copyright © 2010–2025 - Central Government Employees News - Govtempdiary